Fig. 2.
Improvement of cutaneous lesions after 15 months of follow-up, with combined siltuximab and 1,927 nm fractional laser treatment (a–d); dermoscopy showing reduction of erythema, with central scarring area and peripheral hyperpigmentation, in the setting of dermatofibroma-like pattern (e); RCM showing only fibrotic bundles with remodeling of superficial dermis in absence of hyper-reflective inflammatory cells (f).
